Research
Hormonal
Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.
Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.
StrongSupportsmedium confidence
Small observational studies have shown that similar benefits from nontargeted AOMs or off-label pharmacotherapies can be achieved in patients with specific genetic obesity disorders, compared to common multifactorial obesity.
Why this rating
The claim is based on findings from small observational studies.
Source
Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway
Mila S. Welling et al. · Endocrine Reviews · 2025
reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →